Charokopos, Antonios

Abstract Background Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity reaction to Aspergillus species, commonly observed in patients with asthma or cystic fibrosis. However, its occurrence in individuals with chronic obstructive pulmonary disease (COPD) is rare and not well-documented. Radiological findings such as the "finger-in-glove" sign on computed tomography (CT) scans can aid in diagnosis, but a high index of suspicion is required in atypical cases. ABPA can contribute to mucoid impaction, leading to progressive pulmonary dysfunction if left untreated. Case Presentation We report a unique case of ABPA in a patient with COPD who had no prior history of asthma or cystic fibrosis. The patient presented with worsening respiratory symptoms, and imaging studies revealed mucoid impaction with the characteristic "finger-in-glove" sign. Laboratory findings included peripheral eosinophilia and elevated serum IgE, supporting the diagnosis of ABPA. Management involved antifungal therapy and corticosteroids, followed by a tapering regimen, with prophylactic treatment for pneumocystis pneumonia (PCP) to prevent opportunistic infections. Follow-up pulmonary function tests demonstrated a moderate decline in diffusion capacity, necessitating continued monitoring for potential early interstitial lung disease (ILD) or pulmonary hypertension. Conclusions This case highlights the importance of considering ABPA in patients with COPD who present with mucoid impaction, even in the absence of traditional risk factors. A thorough differential diagnosis of eosinophilia in pulmonary disease is crucial to distinguish between hypersensitivity reactions and malignant myeloproliferative disorders, ensuring appropriate treatment strategies. Clinicians should maintain a high level of awareness for ABPA in COPD patients to facilitate timely diagnosis and management.

Nintedanib is a tyrosine kinase inhibitor that was approved for the treatment of patients with idiopathic pulmonary fibrosis in 2014. The most common side effect of Nintedanib is diarrhea, and thrombocytopenia is a rare side effect of Nintedanib. The exact mechanism is unknown, and the literature lacks case reports of this phenomenon. Here, we report the case of a patient who developed thrombocytopenia 12 weeks after starting treatment with Nintedanib. The patient underwent an extensive work up for infectious, hematological, autoimmune, and neoplastic diseases. The patient’s thrombocytopenia resolved following cessation of Nintedanib. This case is significant as it reports a rare side effect that might have detrimental consequences if not recognized and treated timely. Additionally, the onset of thrombocytopenia was delayed, 3 months after the initiation of Nintedanib. We also highlight the various literature regarding drug-induced thrombocytopenia and explore the necessary work-up needed to exclude other potential diagnoses. We hope to advocate for multidisciplinary teams to be aware of patients with pulmonary fibrosis on Nintedanib so that this adverse effect can be recognized promptly.

Recent advances in fibrotic hypersensitivity pneumonitis include improved diagnostic guidance, systematic assessments of immunosuppressive therapy, and the recent availability of antifibrotic therapy (nintedanib) for those with progressive disease. A standardized approach to diagnosis may lead to better inclusion criteria for future therapeutic protocols and delineation of disease or treatment response predictors for real-world management. This review will highlight current diagnostic and treatment challenges and remaining knowledge gaps or areas of uncertainty, with a practical overview of supporting evidence and its clinical implications. Exposure history, serologic testing for antigen sensitivity, bronchoalveolar lavage lymphocytosis, histopathology, and radiologic findings will be covered in the diagnosis section, with immunosuppression, antifibrotic therapy, lung transplantation, and disease prognosis in the treatment and management section.

Abstract Rationale Chronic obstructive pulmonary disease (COPD) is a well-established independent risk factor for lung cancer; however, the literature on the association between asthma and lung cancer is mixed. Whether asthma–COPD overlap (ACO) is associated with lung cancer has not been studied. Objectives We aimed to compare lung cancer risk among patients with ACO versus COPD and other conditions associated with airway obstruction. Methods We studied 13,939 smokers from the National Lung Cancer Screening Trial who had baseline spirometry and used spirometric indices and history of childhood asthma to categorize participants into five specific airway disease subgroups. We used Poisson regression to compare unadjusted and adjusted lung cancer risk. Results The incidence rate of lung cancer per 1,000 person-years was as follows: ACO, 13.2 (95% confidence interval [CI], 8.1–21.5); COPD, 11.7 (95% CI, 10.5–13.1); asthmatic smokers, 1.8 (95% CI, 0.6–5.4); Global Initiative for Chronic Obstructive Lung Disease–Unclassified, 7.7 (95% CI, 6.4–9.2); and normal spirometry smokers, 4.1 (95% CI, 3.5–4.8). Patients with ACO had increased adjusted risk of lung cancer compared with patients with asthma (incidence rate ratio [IRR], 4.5; 95% CI, 1.3–15.8) and normal spirometry smokers (IRR, 2.3; 95% CI, 1.3–4.2) in models adjusting for other risk factors. Adjusted lung cancer incidence in patients with ACO and COPD were not found to be different (IRR, 1.2; 95% CI, 0.7–2.1). Conclusions The risk of lung cancer among patients with ACO is similar to those with COPD and higher than other groups of smokers. These results provide further evidence that COPD, with or without a history of childhood asthma, is an independent risk factor for lung cancer.